Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update
Ultragenyx reported record Q2 revenue of $214 million, a 28% increase from the prior year, driven by strong sales of Crysvita ($156M) and Dojolvi ($27M). The company narrowed its net loss to $92 million, or $0.90 per share, compared to a loss of $115 million in Q2 2025, and reaffirmed 2026 revenue guidance of $730 million to $760 million.
Key figures
- Revenue
- 214000000
- Guidance
- 2026 total revenue $730M-$760M; combined R&D and SG&A flat to slightly down vs 2025; profitability on track for 2027
- Rd expense
- 167000000
- Sga expense
- 88000000
- Cash balance
- 436000000
- Dojolvi revenue
- 27000000
- Evkeeza revenue
- 21000000
- Crysvita revenue
- 156000000
- Mepsevii revenue
- 10000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.